Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
OmniCAR is a novel, covalent, Universal Immune Receptor (UIR) platform technology that overcomes many of the current shortcomings of CAR therapies. OmniCAR enables the post-infusion ability to turn On or OFF CAR activity, dose titratable CAR-Activity for safety/efficacy, in-vivo antigen target re-direction, and ability to multi-arm immune cells.
PTX-100 is a first in class inhibitor of the Ras pathway. Specifically, it inhibits GGT-1, thereby inactivating Rho, Rac and Ral resulting in apoptosis of cancer cells.
PTX-200 is a PH domain inhibitor that inhibits, inter alia, the tumor survival pathway Akt. Its novel MoA overcomes the limitations of other Akt inhibition attempts.